- Home
- WKC vs ANAB Comparison
WKC vs ANAB Comparison
Compare WKC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WKC | ANAB |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WKC | ANAB |
|---|---|---|
| Price | $23.39 | $69.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $28.00 | ★ $74.64 |
| AVG Volume (30 Days) | ★ 560.1K | 557.2K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,916,600,000.00 | $234,603,000.00 |
| Revenue This Year | $0.62 | N/A |
| Revenue Next Year | $3.42 | $31.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $22.21 | $17.11 |
| 52 Week High | $29.85 | $73.30 |
Technical Indicators
Market Signals| Indicator | WKC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 65.01 |
| Support Level | $22.71 | $53.46 |
| Resistance Level | $23.57 | N/A |
| Average True Range (ATR) | 0.50 | 4.39 |
| MACD | 0.11 | 0.81 |
| Stochastic Oscillator | 57.39 | 82.75 |
Price Performance
Historical ComparisonAbout WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).